EXAMETAZIME

Details

Stereochemistry	RACEMIC
Molecular Formula	C13H28N4O2
Molecular Weight	272.387
Optical Activity	( + / - )
Defined Stereocenters	2 / 2
E/Z Centers	2
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](NCC(C)(C)CN[C@H](C)C(\C)=N\O)C(\C)=N\O

InChI

InChIKey=BPNZYADGDZPRTK-UDUYQYQQSA-N

InChI=1S/C13H28N4O2/c1-9(11(3)16-18)14-7-13(5,6)8-15-10(2)12(4)17-19/h9-10,14-15,18-19H,7-8H2,1-6H3/b16-11+,17-12+/t9-,10-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C13H28N4O2
Molecular Weight	272.387
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	2
Optical Activity	UNSPECIFIED

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a44f966-7f5a-4245-88b6-581f71f7b038 | https://www.ncbi.nlm.nih.gov/pubmed/24475210

Technetium (99mTc) exametazime is a radiopharmaceutical agent, which is known as trade name Ceretec. The Ceretec kit is supplied as five packs of three vials for use in the preparation of a technetium Tc99m exametazime intravenous injection as a diagnostic radiopharmaceutical. When technetium Tc99m pertechnetate is added to exametazime in the presence of stannous reductant, a lipophilic technetium Tc99m complex is formed. This lipophilic complex is the active moiety. It converts at approximately 12%/hour to less lipophilic species. When the secondary complex is separated from the lipophilic species, it is unable to cross the blood-brain-barrier. The useful life of the reconstituted agent is limited to 30 minutes. This complex is used as an adjunct in the detection of altered regional cerebral perfusion in stroke. And in addition, is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Also exist clinical trials, where this complex is used for diagnostic purposes in Crohn's Disease and in vascular prosthesis infection.

CNS Activity

Approval Year

Conditions

Condition	Modality	Highest Phase	Product
Stroke 144 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a44f966-7f5a-4245-88b6-581f71f7b038	Diagnostic	Approved 8429	CERETEC Approved Use Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date 1988
Vascular prosthesis infection 1 Sources: https://clinicaltrials.gov/ct2/show/NCT02538133	Diagnostic	Phase III 656	Unknown Approved Use Unknown
Crohn's disease 42 Sources: https://clinicaltrials.gov/ct2/show/NCT01051622	Diagnostic	Phase I 428	CERETEC Approved Use Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date 1988
Intra-abdominal infections 49 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a44f966-7f5a-4245-88b6-581f71f7b038	Diagnostic	Approved 8429	CERETEC Approved Use Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date 1988
Inflammatory bowel disease 19 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a44f966-7f5a-4245-88b6-581f71f7b038	Diagnostic	Approved 8429	CERETEC Approved Use Technetium Tc99m exametazime scintigraphy may be useful as an adjunct in the detection of altered regional cerebral perfusion in stroke. Tc99m exametazime is indicated for leukocyte labeled scintigraphy as an adjunct in the localization of intra-abdominal infection and inflammatory bowel disease. Launch Date 1988

PubMed

Title	Date	PubMed
Effects of methylene blue stabilizer on in vitro viability and chemotaxis of 99mTc-exametazime-labeled leukocytes.	2002 Jul	12097465

Patents

Sample Use Guides

In Vivo Use Guide

The normal adult (70 kg) dose is 0.259-0.925 GBq (7-25 mCi) as Tc99m labeled leukocytes by intravenous injection. Optimal planar imaging is between 2-4 hours. Do not use methylene blue in the preparation of the Tc99m labeled leukocytes. Cerebral Scintigraphy: The recommended dose range for i.v. administration, of reconstituted sodium pertechnetate Tc99m exametazime (with or without methylene blue) in the average adult (70 kg) is 370-740 MBq (10-20 mCi). Dynamic imaging may be performed between 0 to 10 minutes following injection. Static imaging may be performed from 15 minutes up to 6 hours after injection.

Route of Administration: Intravenous

In Vitro Use Guide

Whole blood (480 mL) was obtained from each of 3 healthy donors and divided equally into eight 60-mL aliquots. Two aliquots from each of the 3 subjects were used as a control (i.e., leukocytes were not labeled with either nonstabilized or stabilized 99mTc-exametazime) in this study. The remaining 6 aliquots from each of the 3 subjects were divided equally into the following formulation groups: (a) leukocytes labeled with nonstabilized 99mTc-exametazime, (b) leukocytes labeled with stabilized 99mTc-exametazime containing 250 microg methylene blue, and (c) leukocytes labeled with stabilized 99mTc-exametazime containing 500 microg methylene blue. It was revealed that, the methylene blue/phosphate buffer stabilizer (250 or 500 microg methylene blue) did not affect the cell membrane integrity, chemotactic capacity, labeling efficiency, in vitro stability, or complete blood count of leukocytes labeled with stabilized 99mTc-exametazime.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 17:51:06 GMT 2023` Edited by `admin` on `Sat Dec 16 17:51:06 GMT 2023`
Record UNII	G29272NCKL
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EXAMETAZIME

Official Name

English

DL-HM-PAO

Code

English

EXAMETAZIME [JAN]

Common Name

English

Exametazime [WHO-DD]

Common Name

English

DL HM-PAO

Code

English

exametazime [INN]

Common Name

English

DL-HEXAMETHYLPROPYLENE AMINE OXIDE

Common Name

English

(±)-(3RS,3'RS)-3,3'-((2,2-DIMETHYLTRIMETHYLENE)DIIMINO)DI-2-BUTANONE (E,E)-DIOXIME

Common Name

English

EXAMETAZIME [MI]

Common Name

English

EXAMETAZIME [II]

Common Name

English

2-BUTANONE, 3,3'-((2,2-DIMETHYL-1,3-PROPANEDIYL)DIIMINO)BIS-, DIOXIME, (R*,R*-(E,E))-(±)-

Common Name

English

EXAMETAZIME [USAN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C1937